EUVIMEDEUVIMED entdecken
Crossref

Inhibition of METTL3 promotes mesangial cell mitophagy and attenuates glomerular damage by alleviating FOSL1 m6A modifications via IGF2BP2-dependent mechanisms

Tao Liu, Xing Xing Zhuang, Xiao Li Zhu, Xi Wu, Xiu Juan Qin, Liang Bing Wei, Ya Chen Gao, Jia Rong Gao

Biochemical Pharmacology · 2025

DOI: 10.1016/j.bcp.2025.116867 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2025. Verfasst von Tao Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230012 Anhui, China; College of Pharmacy, Anhui …. Hauptthemen laut MEDLINE: Methyltransferases, Mesangial Cells, Mitophagy, RNA-Binding Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epigenetic changes are involved in many physiological and pathological processes. Mitophagy plays a critical role in chronic kidney disease (CKD); however, the role of N6-methyladenosine (m6A) modification in renal mitophagy remains unclear. In this research, we aim to elucidate the role of RNA methylation in modulating mitophagy and its involvement in the pathophysiology of chronic glomerulonephritis (CGN). We found that Methyltransferase-like 3 (METTL3) was significantly upregulated in biopsies from CKD patients, as well as in CGN mice and cultured mouse mesangial cells (MMCs), and was inversely correlated with glomerular filtration rate. Adeno-associated virus serotype 9 (AAV9)-mediated METTL3 silencing from mouse kidneys attenuated adenine-induced glomerular damage, and promoted renal mitophagy. METTL3 knockdown significantly reduced the oxidative stress and inflammation levels and promoted mitophagy in lipopolysaccharide (LPS)-stimulated MMCs, while its overexpression significantly aggravated these responses in vitro. Moreover, FOSL1 (Fos-like antigen 1) was identified as a target of METTL3 and the stability of FOSL1 was increased through binding of IGF2BP2 (Insulin-like Growth Factor 2 mRNA-binding Protein 2) to its m6A-modified regions. The mitophagy regulatory effects of FOSL1 were then explored both in vitro and in vivo. Mechanistically, METTL3 modulated AMPK (AMP-activated Protein Kinase)/mTOR (Mechanistic Target of Rapamycin) signaling via the m6A modification of FOSL1 in an IGF2BP2-dependent manner and exerted a mitophagy inhibitory effect. In summary, this study suggested that METTL3-mediated m6A modification is an important mechanism of mesangial cell (MCs) injury in CGN. Targeting m6A through the writer enzyme METTL3 is a potential approach for the treatment of CGN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethyltransferasesMesangial CellsMitophagyRNA-Binding ProteinsProto-Oncogene Proteins c-fosAdenosineKidney GlomerulusAnimalsMiceHumansMaleMice, Inbred C57BLCells, CulturedRenal Insufficiency, Chronic

Stichwörter der Autor:innen

Chronic glomerulonephritics (CGN)FOSL1 (Fos-like antigen 1)IGF2BP2 (Insulin-like Growth Factor 2 mRNA-binding Protein 2)METTL3 (Methyltransferase-like 3)Mesangial cells (MCs)MitophagyN6-methyladenosine (m6A)

Substanzen

MethyltransferasesRNA-Binding ProteinsMETTL3 protein, humanMettl3 protein, mouseProto-Oncogene Proteins c-fosAdenosineN-methyladenosine

Autor:innen und Institutionen

  • Department of Pharmacy, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230012 Anhui, China; College of Pharmacy, Anhui University of Chinese Medicine, Hefei 230011 Anhui, China.
  • Department of Pharmacy, Chaohu Hospital of Anhui Medical University, Chaohu 238000 Anhui, China.
  • Department of Pharmacy, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230012 Anhui, China.
  • Nephrology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230012 Anhui, China.
  • Department of Pharmacy, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230012 Anhui, China; Anhui Provincial Key Laboratory of Chinese Medicinal Formula, Hefei 230012 Anhui, China. Electron…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Liu, T., Zhuang, X. X., Li Zhu, X., Wu, X., Juan Qin, X., Bing Wei, L., Chen Gao, Y., & Rong Gao, J. (2025). Inhibition of METTL3 promotes mesangial cell mitophagy and attenuates glomerular damage by alleviating FOSL1 m6A modifications via IGF2BP2-dependent mechanisms. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2025.116867

Vancouver

Liu T, Zhuang XX, Li Zhu X, Wu X, Juan Qin X, Bing Wei L, et al. Inhibition of METTL3 promotes mesangial cell mitophagy and attenuates glomerular damage by alleviating FOSL1 m6A modifications via IGF2BP2-dependent mechanisms. Biochemical Pharmacology. 2025. doi:10.1016/j.bcp.2025.116867

BibTeX
@article{Liu2025,
  author = {Liu, Tao and Zhuang, Xing Xing and Li Zhu, Xiao and Wu, Xi and Juan Qin, Xiu and Bing Wei, Liang and Chen Gao, Ya and Rong Gao, Jia},
  title = {Inhibition of METTL3 promotes mesangial cell mitophagy and attenuates glomerular damage by alleviating FOSL1 m6A modifications via IGF2BP2-dependent mechanisms},
  journal = {Biochemical Pharmacology},
  year = {2025},
  doi = {10.1016/j.bcp.2025.116867}
}
Kostenlos starten →